Even though these seniors tested positive, as the article points out all but one of them was asymptomatic, so the single dose of the vaccine may very well have done enough to help them avoid a serious infection.
We should also note that it's only the Pfizer vaccine where there's no actual data to support a delayed second dose.
With the Oxford-AstraZeneca vaccine, there were enough trial participants that didn't receive the second dose until twelve weeks (or so) after the first, that there is sufficient evidence to show that even one dose gives a good level of protection.
We should also note that it's only the Pfizer vaccine where there's no actual data to support a delayed second dose.
With the Oxford-AstraZeneca vaccine, there were enough trial participants that didn't receive the second dose until twelve weeks (or so) after the first, that there is sufficient evidence to show that even one dose gives a good level of protection.
Last edited: